Εμφάνιση απλής εγγραφής

dc.creatorHatzakis, A.en
dc.creatorVan Damme, P.en
dc.creatorAlcorn, K.en
dc.creatorGore, C.en
dc.creatorBenazzouz, M.en
dc.creatorBerkane, S.en
dc.creatorButi, M.en
dc.creatorCarballo, M.en
dc.creatorCortes Martins, H.en
dc.creatorDeuffic-Burban, S.en
dc.creatorDominguez, A.en
dc.creatorDonoghoe, M.en
dc.creatorElzouki, A. N.en
dc.creatorBen-Alaya Bouafif, N.en
dc.creatorEsmat, G.en
dc.creatorEsteban, R.en
dc.creatorFabri, M.en
dc.creatorFenton, K.en
dc.creatorGoldberg, D.en
dc.creatorGoulis, I.en
dc.creatorHadjichristodoulou, T.en
dc.creatorHatzigeorgiou, T.en
dc.creatorHamouda, O.en
dc.creatorHasurdjiev, S.en
dc.creatorHughes, S.en
dc.creatorKautz, A.en
dc.creatorMalik, M.en
dc.creatorManolakopoulos, S.en
dc.creatorMatičič, M.en
dc.creatorPapatheodoridis, G.en
dc.creatorPeck, R.en
dc.creatorPeterle, A.en
dc.creatorPotamitis, G.en
dc.creatorPrati, D.en
dc.creatorRoudot-Thoraval, F.en
dc.creatorReic, T.en
dc.creatorSharara, A.en
dc.creatorShennak, M.en
dc.creatorShiha, G.en
dc.creatorShouval, D.en
dc.creatorSočan, M.en
dc.creatorThomas, H.en
dc.creatorThursz, M.en
dc.creatorTosti, M.en
dc.creatorTrépo, C.en
dc.creatorVince, A.en
dc.creatorVounou, E.en
dc.creatorWiessing, L.en
dc.creatorManns, M.en
dc.date.accessioned2015-11-23T10:29:58Z
dc.date.available2015-11-23T10:29:58Z
dc.date.issued2013
dc.identifier10.1111/jvh.12120
dc.identifier.issn13520504
dc.identifier.urihttp://hdl.handle.net/11615/28449
dc.description.abstractThe burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to viral hepatitis remains largely unrecognized, including in high-risk groups and migrants, because of a lack of reliable epidemiological data, suggesting the need for better and targeted surveillance for public health gains. In many countries, the burden of chronic liver disease due to hepatitis B and C is increasing due to ageing of unvaccinated populations and migration, and a probable increase in drug injecting. Targeted vaccination strategies for hepatitis B virus (HBV) among risk groups and harm reduction interventions at adequate scale and coverage for injecting drug users are needed. Transmission of HBV and hepatitis C virus (HCV) in healthcare settings and a higher prevalence of HBV and HCV among recipients of blood and blood products in the Balkan and North African countries highlight the need to implement and monitor universal precautions in these settings and use voluntary, nonremunerated, repeat donors. Progress in drug discovery has improved outcomes of treatment for both HBV and HCV, although access is limited by the high costs of these drugs and resources available for health care. Egypt, with the highest burden of hepatitis C in the world, provides treatment through its National Control Strategy. Addressing the burden of viral hepatitis in the Balkan and Mediterranean regions will require national commitments in the form of strategic plans, financial and human resources, normative guidance and technical support from regional agencies and research. © 2013 John Wiley & Sons Ltd.en
dc.source.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-84879953822&partnerID=40&md5=646ef58402095788fdc931b03c07a70d
dc.subjectBalkan regionen
dc.subjecthepatitis Ben
dc.subjecthepatitis Cen
dc.subjecthepatocellular carcinomaen
dc.subjectMediterraneanen
dc.subjectnorthern Africaen
dc.subjectsurveillanceen
dc.subjectadefoviren
dc.subjectbocepreviren
dc.subjectentecaviren
dc.subjecthepatitis B surface antigenen
dc.subjecthepatitis B(e) antigenen
dc.subjectinterferonen
dc.subjectlamivudineen
dc.subjectpeginterferon alpha2aen
dc.subjectribavirinen
dc.subjecttelapreviren
dc.subjecttelbivudineen
dc.subjecttenofoviren
dc.subjectvirus vaccineen
dc.subjectagingen
dc.subjectawarenessen
dc.subjectBalkan Peninsulaen
dc.subjectblood donoren
dc.subjectblood safetyen
dc.subjectblood transfusionen
dc.subjectchronic liver diseaseen
dc.subjectconference paperen
dc.subjectcost effectiveness analysisen
dc.subjectdrug costen
dc.subjectdrug useen
dc.subjectharm reductionen
dc.subjecthealth care accessen
dc.subjecthealth care personnelen
dc.subjectHepatitis B virusen
dc.subjectHepatitis C virusen
dc.subjectHepatitis delta virusen
dc.subjecthigh risk populationen
dc.subjecthumanen
dc.subjectinfection controlen
dc.subjectmeta analysis (topic)en
dc.subjectmigrationen
dc.subjectmorbidityen
dc.subjectmortalityen
dc.subjectopiate substitution treatmenten
dc.subjectoutcome assessmenten
dc.subjectpractice guidelineen
dc.subjectprevalenceen
dc.subjectpriority journalen
dc.subjectpublic health problemen
dc.subjectseroprevalenceen
dc.subjectsexual intercourseen
dc.subjectsexually transmitted diseaseen
dc.subjectSouthern Europeen
dc.subjectsystematic review (topic)en
dc.subjecttreatment durationen
dc.subjectvaccinationen
dc.subjectvirus transmissionen
dc.subjectworld health organizationen
dc.subjectAntiviral Agentsen
dc.subjectCarcinoma, Hepatocellularen
dc.subjectCross Infectionen
dc.subjectDisease Transmission, Infectiousen
dc.subjectEpidemiological Monitoringen
dc.subjectHepatitis B Vaccinesen
dc.subjectHepatitis B, Chronicen
dc.subjectHepatitis C, Chronicen
dc.subjectHumansen
dc.subjectLiver Neoplasmsen
dc.subjectMediterranean Regionen
dc.subjectTreatment Outcomeen
dc.titleThe state of hepatitis B and C in the mediterranean and balkan countries: Report from a summit conferenceen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής